[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Biomaven Peter Suzman

Peter Suzman posts on X about $hrow, $4507t, drugs, soda the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXXX engagements in the last XX hours.

Engagements: XXXXXX #

X Week XXXXXX +483%
X Month XXXXXX +118%
X Months XXXXXXX +238%
X Year XXXXXXX +142%

Mentions: X #

X Week X +13%
X Month XX +38%
X Months XXX +23%
X Year XXX +106%

Followers: XXXXX #

X Week XXXXX +0.13%
X Month XXXXX +0.66%
X Months XXXXX +5%
X Year XXXXX +7.90%

CreatorRank: XXXXXXX #

Social Influence #

Social category influence stocks XXXXX% finance XXXX%

Social topic influence $hrow 11.11%, $4507t 11.11%, drugs 5.56%, soda 5.56%, $sgioy 5.56%, pfe 5.56%, ip 5.56%, $sny 5.56%, $lly 5.56%, $jnj XXXX%

Top accounts mentioned or mentioned by @snupsnus @nightowlbiotech @jamesekrause @2000manbiotech @biotechforever @jakebackpack @lyssiotislab @robohogs @zipjet @schnectady @jimmysil @nickthename @14655116677a @jbarnes1223 @mortigaunt @towiu2 @matagi1996 @mortigaunt_ @yaireinhorn @phototogboy

Top assets mentioned Synthetify (SNY) Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) Merck & Co., Inc. (MRK) Pfizer, Inc. (PFE) Bristol-Myers Squibb Co (BMY) AbbVie Inc (ABBV) Regeneron Pharmaceuticals Inc (REGN) Amgen, Inc. (AMGN)

Top Social Posts #

Top posts by engagements in the last XX hours

"Been thinking more about the $HROW biosimilar deal. The key here is that most biosimilar marketing is payer-centric - once there are multiple players (as there are already for Lucentis) it's all been about convincing payers to chose your product in an environment of rapidly declining ASPs. But these drugs are largely in-office buy-and-bill so a prescriber-centric approach makes much more sense. Further there is significant cost-pressure from payers - indeed some dozen insurers (like BCBS Michigan) even require step-therapy starting with off-label compounded Avastin. (Medicare Advantage payers"
@Biomaven on X 2025-07-18 14:59:43 UTC 8505 followers, 1451 engagements

"Sucrose (cane sugar) is virtually identical to high-fructose corn syrup. Human trials have never shown a difference but a few rodent studies at high doses show more liver issues with HFCS. Unlikely to my mind that this move will have much impact (except maybe to Archer-Daniel-Midland and corn farmers)"
@Biomaven on X 2025-07-22 16:51:46 UTC 8505 followers, 2000 engagements

"Next gen SARS-CoV-2 inhibitor from Shionogi - some 30x more potent than ensitrelvir (which in turn is significantly more potent than Paxlovid)"
@Biomaven on X 2025-07-06 02:26:51 UTC 8505 followers, 1264 engagements

"Last week bought my first new biopharma stock in quite a while - the midcap Japanese pharma Shionogi (ADR symbol $SGIOY. The play here is their SARS-CoV-2 antiviral Ensitrelvir directed against the same target as Paxlovid"
@Biomaven on X 2022-11-11 19:22:27 UTC 8504 followers, XX engagements

"$MRK with Keytruda patent expiration is in the biggest hole"
@Biomaven on X 2025-07-21 20:18:51 UTC 8505 followers, 1550 engagements

"@jakebackpack 5000kg is about 1/1000 of current annual production so unlikely to have much impact. And of course only a very tiny fraction of existing stocks. That paper seems to make light of the cost of separating the needed mercury isotope though"
@Biomaven on X 2025-07-22 20:01:53 UTC 8505 followers, 14.6K engagements

"@LyssiotisLab "These parallels suggest that sleep pressure and hunger both have mitochondrial origins and that electrons flow through the respiratory chains of the respective feedback controllers like sand in the hourglass that determines when balance must be restored.""
@Biomaven on X 2025-07-19 23:03:25 UTC 8503 followers, XXX engagements

"The Eylea biosimilar space is a bit of a mess right now. $REGN formulation patent seems to expire in 2027 but they have a deal for another competitor to enter in 2026 and $AMGN is already on the market at-risk (they don't use a buffer). So likely for $HROW this will be a 2027 story but same dynamics apply as for Lucentis. So then I would see tremendous financial incentives for payers to require Eylea biosimilar step-therapy before paying for Eylea HD or Vabysmo"
@Biomaven on X 2025-07-18 14:59:44 UTC 8504 followers, 1106 engagements

"@Nick_The_Name @14655116677A @jbarnes1223 Very significant costs in first separating the mercury isotope. And I don't know what radioactivity issues they will have to deal with as well"
@Biomaven on X 2025-07-22 22:09:55 UTC 8505 followers, XXX engagements

"@Mortigaunt_ Yes you do need dispatchable power. But with battery prices continuing to crater an increasing amount can come from that. Fusion (or nuclear) will have to compete with solar+battery+natgas peakers"
@Biomaven on X 2025-07-22 22:39:45 UTC 8505 followers, XXX engagements